Christine-Elke Ortmann
Overview
Explore the profile of Christine-Elke Ortmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
712
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zouboulis C, Kyrgidis A, Alavi A, Jemec G, Martorell A, Marzano A, et al.
J Eur Acad Dermatol Venereol
. 2024 Oct;
PMID: 39425517
Introduction: The International Hidradenitis Suppurativa Severity Score System (IHS4) is a validated tool that measures inflammatory lesions, including draining tunnels, in hidradenitis suppurativa (HS). Objective: To evaluate secukinumab efficacy using...
2.
Zouboulis C, Prens E, Sayed C, Molina-Leyva A, Bettoli V, Romanelli M, et al.
J Eur Acad Dermatol Venereol
. 2023 Dec;
38(6):e496-e499.
PMID: 38058224
No abstract available.
3.
Sticherling M, Nikkels A, Hamza A, Kwong P, Szepietowski J, El Sayed M, et al.
Am J Clin Dermatol
. 2023 Jun;
24(5):821-835.
PMID: 37341961
Background: Plaque psoriasis affects ~ 1% of the pediatric population, negatively impacting quality of life. The efficacy and safety of secukinumab in pediatric patients with moderate to severe or severe...
4.
Krueger J, Langley R, Nigen S, Kasparek T, Di Comite G, Ortmann C, et al.
Exp Dermatol
. 2023 Jun;
32(10):1834-1847.
PMID: 37272375
Interleukin (IL)-23-independent IL-17A production has been suggested to be involved in persistent manifestations of psoriatic disease, including anti-IL-12/23-refractory psoriatic plaques; this study aimed to test this hypothesis by investigating the...
5.
Alpalhao M, Duarte J, Diogo R, Vandemeulebroecke M, Ortmann C, Kasparek T, et al.
BioDrugs
. 2022 Nov;
36(6):781-789.
PMID: 36334236
Background: The impact of psoriasis, response to treatment, and patients' perceptions of treatment satisfaction vary by body area. Objectives: We aimed to evaluate the level of response in lower limbs...
6.
Conrad C, Ortmann C, Vandemeulebroecke M, Kasparek T, Reich K
Dermatol Ther (Heidelb)
. 2021 Dec;
12(1):233-241.
PMID: 34870789
Introduction: Patients with plaque psoriasis may experience varying levels of treatment response to different biologics, based on phenotypic characteristics and underlying genetic factors. Nail psoriasis is a common manifestation of...
7.
Hochhaus A, Larson R, Guilhot F, Radich J, Branford S, Hughes T, et al.
N Engl J Med
. 2017 Mar;
376(10):917-927.
PMID: 28273028
Background: Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses on the basis of more than 10...
8.
Wang J, Shen Z, Saglio G, Jin J, Huang H, Hu Y, et al.
Blood
. 2015 Mar;
125(18):2771-8.
PMID: 25766724
Treatment with a tyrosine kinase inhibitor (TKI) targeting BCR-ABL1 is currently the standard of care for patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP). In this study, we...
9.
Baccarani M, Druker B, Branford S, Kim D, Pane F, Mongay L, et al.
Int J Hematol
. 2014 Mar;
99(5):616-24.
PMID: 24658916
The TOPS trial evaluated high- (800 mg/day; n = 319) versus standard-dose (400 mg/day; n = 157) imatinib in patients newly diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia in chronic...
10.
Jarrett S, Conaghan P, Sloan V, Papanastasiou P, Ortmann C, OConnor P, et al.
Arthritis Rheum
. 2006 Apr;
54(5):1410-4.
PMID: 16645968
Objective: Bisphosphonates inhibit osteoclast activity, which is central to the development of bone damage in rheumatoid arthritis (RA). The aim of this study was to assess whether treatment with zoledronic...